Calcium channel blocker are available in short acting and long acting form. The response of short acting medication is quick as compare to long acting calcium channel blocker drugs. Amlodipine (Norvasc), Diltiazem (Cardizem, Tiazac, others), Felodipine, Isradipine, Nicardipine are the type of calcium channel blocker drug used for the treatment of coronary artery disease, chest pain (angina), irregular heartbeats (arrhythmia) and blood vessel conditions, such as Raynaud's disease.
The global calcium channel blocker drugs market is estimated to be valued at US$ 14,285.3 million in 2022 and expected to exhibit a CAGR of 5.2% over the forecast period (2022-2030).
Figure 1. Global Calcium Channel Blocker Drugs Market Share (%) in Terms of Value, by Region, 2022
Increasing prevalence of hypertension is expected to aid in the growth of the global calcium channel blocker drugs market
According to the World Health Organization 2021, hypertension is a major cause of premature death worldwide.
Moreover, according to the Million Hearts managed by the Centers for Disease Control and Prevention, around 1 out of 2 adults in the U.S. suffer from hypertension. In addition, around 91.7 million adult in the U.S. are recommended prescription medication with lifestyle modifications.
|Base Year:||2021||Market Size in 2022:||US$ 14,285.3 Mn|
|Historical Data for:||2017 to 2021||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||5.2%||2030 Value Projection:||US$ 21,489.7 Mn|
Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc
|Restraints & Challenges:||
Figure 2. Global Calcium Channel Blocker Drugs Market Share (%), by Drug Class, 2022
Global Calcium Channel Blocker Drugs Market: Restraint
Side effects associated with to calcium channel blockers drug such as, headache, rapid heart rate, edema and constipation are expected to inhibit the market growth during the forecast period for the companies and products.
Major players operating in the global calcium channel blocker drugs market include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
Calcium channel blockers are class of medicines used for the treatment of hypertension, irregular heartbeats called arrhythmias and chest pain related to angina they work by blocking some of the calcium that enters the heart and arteries. Calcium channel blocker drugs are available in many forms which ranging from short-acting dissolving tablets to extended-release capsules. The dosage will depend on overall health and medical history of patients.
Moreover, chronic kidney disease is the progressive loss of kidney function over a period of several years. As kidney failure advances to further stages, and the organ’s function is severely impaired, dangerous levels of waste and fluid can rapidly build up in the body. Treatment is aimed at stopping or slowing down the progression of the disease – this is usually done by controlling its underlying cause calcium channel blockers are drug used in the treatment of chronic kidney disease or its underlying cause.
Increasing prevalence of cardiovascular disease, obesity, unhealthy life style is expected to drive the market growth during the forecast period.
For instance, according to the World Health Organization 2022, an estimated 17.9 million people are died from cardiovascular disease in 2019 form which 85% death are occur due to heart attack and stroke worldwide.
Increasing lunches and approval of calcium channel blocker drug is expected to witness significant growth of the market over the forecast period
For instance, in June 2022, CMP Pharma, Inc., a pharmaceutical company receive the U.S. Food and Drug Administration approval for its Norliqva (amlodipine) oral solution, 1 mg/mL, an oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker for the treatment of hypertension in patients 6 years of age and older.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.